deltatrials
Completed PHASE4 INTERVENTIONAL 7-arm NCT03489018

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (FPCV)

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan Infants

Sponsor: Bill and Melinda Gates Foundation

Conditions Invasive Pneumococcal Disease, Protection Against Pneumococcal Infection Streptococcus Pneumoniae Infection
Interventions PCV10 PCV13
Updated 13 times since 2018 Last updated: Nov 8, 2024 Started: Mar 21, 2019 Primary completion: Sep 30, 2022 Completion: Nov 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Invasive Pneumococcal Disease, Protection Against and Pneumococcal Infection and is currently completed. Bill and Melinda Gates Foundation leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Sep 2019 · 6 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Oct 2020 · 7 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshot

Change History

13 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE4

  4. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE4

  5. Apr 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE4

▶ Show 8 earlier versions

  1. Apr 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE4

    Status: Unknown Status → Active Not Recruiting

  2. Mar 2022 — Apr 2022 [monthly]

    Unknown Status PHASE4

    Status: Recruiting → Unknown Status

  3. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE4

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  5. Mar 2020 — Oct 2020 [monthly]

    Recruiting PHASE4

  6. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  7. Mar 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE4

  8. Dec 2018 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bill and Melinda Gates Foundation
  • KEMRI-Wellcome Trust Collaborative Research Program
  • London School of Hygiene and Tropical Medicine
  • National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU)
  • University College, London
  • Wellcome Trust
Data source: London School of Hygiene and Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations